Non-Hispanic Black women have worse breast cancer outcomes compared to White women, according to a study published published in the Journal of the National Cancer Institute. In this study, researchers analyzed 4,048 women from the phase III RxPONDER trial and its impact on treatment for node-positive(1-3), hormone receptor-positive, HER2-negative breast cancer. This trial randomized women to endocrine therapy (ET) or to chemotherapy plus ET. The primary end point of interest was defined as invasive disease-free ...